Skip to main content

Mitotane Disease Interactions

There are 5 disease interactions with mitotane.

Major

Mitotane (applies to mitotane) adrenal insufficiency

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral, Shock

Mitotane inhibits production of corticosteroids and alters extra-adrenal metabolism of endogenous and exogenous steroids. All patients treated with mitotane should be instructed to immediately report signs and symptoms of infection or other illnesses. Therapy with mitotane should be withheld immediately following shock or severe trauma or infection. Exogenous steroids should be administered since the suppressed adrenal may not immediately begin to secrete steroids.

Switch to professional interaction data

Moderate

Mitotane (applies to mitotane) depression

Moderate Potential Hazard, Moderate plausibility.

Symptoms of depression consisting of lethargy and somnolence have been reported during mitotane therapy. Therapy with mitotane should be administered cautiously to patients with or predisposed to depression. Clinical monitoring of psychological behavior is recommended.

Switch to professional interaction data

Moderate

Mitotane (applies to mitotane) liver dysfunction

Moderate Potential Hazard, High plausibility. Applicable conditions: Liver Disease

Mitotane is primarily metabolized by the liver. Metabolism and therapeutic activity may be altered in patients with hepatic impairment. Therapy with mitotane should be administered cautiously in patients with hepatic impairment. Clinical monitoring of hepatic function is recommended.

Switch to professional interaction data

Moderate

Mitotane (applies to mitotane) neurologic disorder

Moderate Potential Hazard, High plausibility.

Unspecified brain damage and impairment of function have been reported during prolonged mitotane therapy. Therapy with mitotane should be administered cautiously to patients with neurologic impairment. Clinical monitoring of behavior and neurological function is recommended when continuous mitotane therapy exceeds two years.

Switch to professional interaction data

Moderate

Mitotane (applies to mitotane) perimenopause

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Menopausal Disorder

Ovarian macrocysts, often bilateral and multiple, have been reported in premenopausal patients receiving mitotane which might lead to adnexal torsion and hemorrhagic cyst rupture. It is recommended to use care when using this agent in premenopausal patients and to seek medical care if they experience gynecological symptoms such as vaginal bleeding and/or pelvic pain.

Switch to professional interaction data

Mitotane drug interactions

There are 609 drug interactions with mitotane.

Mitotane alcohol/food interactions

There is 1 alcohol/food interaction with mitotane.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer